Cargando…
Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
The hypothalamic neuroendocrine catecholamine dopamine regulates the lactotroph function, including prolactin (PRL) secretion, proliferation, and apoptosis. The treatment of PRL-secreting tumors, formerly known as prolactinomas, has relied mainly on this physiological characteristic, making dopamine...
Autor principal: | Ferraris, Jimena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877409/ https://www.ncbi.nlm.nih.gov/pubmed/36714572 http://dx.doi.org/10.3389/fendo.2022.1057749 |
Ejemplares similares
-
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019) -
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
por: Tang, Hao, et al.
Publicado: (2021) -
Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
por: Gonzaga, Maria de Fátima de Magalhães, et al.
Publicado: (2018) -
Association of prolactin receptor (PRLR) variants with prolactinomas
por: Gorvin, Caroline M, et al.
Publicado: (2019) -
SUN-289 Symptomatic Prolactinoma with Modestly Elevated Prolactin Levels: A Cautionary Tale
por: Raisingani, Manish
Publicado: (2019)